Paratek Pharmaceuticals Inc represents values of innovation, dedication, and patient-centric approach. With a strong corporate philosophy, the company is committed to developing novel therapies to improve the lives of patients. Paratek focuses on advancing treatments for infectious diseases and strives to fill unmet medical needs. The company's dedication to scientific excellence and collaboration drives its mission to discover and deliver innovative solutions that address global health challenges. By prioritizing patient well-being, Paratek Pharmaceuticals Inc aims to make a positive impact in the healthcare industry and improve outcomes for individuals worldwide.

Paratek Pharmaceuticals Inc is primarily present in the United States.

Paratek Pharmaceuticals Inc has achieved significant milestones in its history. One notable accomplishment is the FDA approval of their antibiotic, NUZYRA, for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Additionally, Paratek has successfully developed and commercialized SEYSARA, an oral therapeutic for moderate to severe acne. Their commitment to research and innovation has contributed to their continued growth and success in the pharmaceutical industry.

Paratek Pharmaceuticals Inc is a renowned pharmaceutical company focused on developing and commercializing innovative therapies to address infectious diseases. Established in 1996, Paratek has dedicated its efforts to combating antibiotic resistance and finding solutions for difficult-to-treat infections. The company has successfully developed and received FDA approval for multiple antibiotics, including Nuzyra® (omadacycline) and Seysara® (sarecycline). By leveraging its expertise in chemistry and microbiology, Paratek aims to improve patient outcomes and meet the growing medical needs in the field of infectious diseases. With a strong commitment to research and development, Paratek Pharmaceuticals Inc continues to contribute to the advancement of patient care worldwide.

The main competitors of Paratek Pharmaceuticals Inc in the market include companies such as Novartis AG, Pfizer Inc, Johnson & Johnson, and GlaxoSmithKline.

Paratek Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

Paratek Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies to treat serious and life-threatening diseases. The company's business model revolves around identifying and acquiring or licensing novel compounds that have the potential to address significant unmet medical needs. Paratek Pharmaceuticals Inc aims to develop and bring these compounds through advanced stages of clinical development, seeking regulatory approval, and ultimately commercializing them to provide impactful treatments for patients. By employing a strategic approach to research, development, and collaborations, Paratek Pharmaceuticals Inc strives to improve the lives of patients while delivering value to its stakeholders.

مُعامل القيمة السوقية إلى الأرباح لـ Paratek Pharmaceuticals هو ٧٢٫٨٨.

مُعامِل القيمة إلى المبيعات Paratek Pharmaceuticals هو ٠٫٥٤.

نقاط جودة AlleAktien لـ Paratek Pharmaceuticals هي 6/10.

المتوقعة Paratek Pharmaceuticals الإيرادات هي ٢٢٥٫٨٥ مليون. USD.

صافي الربح المتوقعة Paratek Pharmaceuticals هو ١٫٦٦ مليون. USD.

Paratek Pharmaceuticals Inc is a biotechnology company that focuses on the development of antibiotics for use in human medicine. The company's business model includes both research and development and the sale of products. Paratek's product range includes several antibiotics that can be used to treat bacterial infections. One of the company's key products is NUZYRA, an antibiotic used for the treatment of skin and soft tissue infections as well as pneumonia. Additionally, the company offers SEYSARA, a medication for the treatment of acne. Paratek also conducts research and development activities to develop new antibiotics. The company particularly focuses on developing antibiotics against Gram-negative bacteria, which are responsible for severe infections such as pneumonia and sepsis. Paratek collaborates closely with other companies and research institutions to develop new drugs and advance research in this field. In addition, Paratek provides services to support physicians and healthcare facilities in the diagnosis and treatment of infections. For example, the company provides training materials and guidelines to help physicians select the best antibiotic for their patients. An important pillar of Paratek's business model is collaboration with other companies. The company has partnerships with several major pharmaceutical companies such as Allergan and Zai Lab to market and distribute its products worldwide. These partnerships allow Paratek to expand its reach and influence in the pharmaceutical industry. Paratek is also committed to producing its products and services in a sustainable and environmentally friendly manner. The company advocates for environmentally friendly procurement and strives for continuous improvement of its environmental impact. Overall, the business model of Paratek Pharmaceuticals Inc offers a wide range of products and services for the medical community. The focus on developing antibiotics against difficult-to-treat infections and the collaboration with other companies allows Paratek to expand its reach and influence in the pharmaceutical industry.

يوزع Paratek Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Paratek Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـParatek Pharmaceuticals هو US6993743029.

رمز WKN لـ Paratek Pharmaceuticals هو A12EGE.

الرمز المُختصر لـ Paratek Pharmaceuticals هو PRTK.

خلال آخر 12 شهراً، دفعت Paratek Pharmaceuticals توزيعات أرباح بقيمة ٢٣٫٩٧ USD . وهذا يعادل عائد توزيعات أرباح يقارب ١٬٠٧٤٫٨٣ %. ومن المتوقع أن تدفع Paratek Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Paratek Pharmaceuticals هي ١٬٠٧٤٫٨٣ %.

Paratek Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Paratek Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Paratek Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٨٫٠٠٩ USD من Paratek Pharmaceuticals المُعلن عنها في ٢٩‏/١٠‏/٢٠١٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٣١‏/١٠‏/٢٠١٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٢٩‏/١٠‏/٢٠١٤.

في العام 2024، وزعت Paratek Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Paratek Pharmaceuticals بالعملة USD.